Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 5Neuroendocrine Tumors 5Thyroid Cancer, Papillary 3Adenocarcinoma, Follicular 3Thyroid Neoplasms 2Paraganglioma, Extra-Adrenal 2Carcinoma, Medullary 2Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Thyroid Cancer Metastatic 1Pheochromocytoma 1Multiple Endocrine Neoplasia Type 1 1Differentiated Thyroid Cancer (DTC) 1Differentiated Thyroid Cancer 1Carcinoma, Neuroendocrine 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1Adrenocortical Carcinoma 1

Interventions

vandetanib 1sacubitril and valsartan sodium hydrate drug combination 1lenvatinib 1fluorodopa F 18 1cabozantinib 1Sorafenib 13-(3'-adamantan-1-yl-4'-methoxybiphenyl-4-yl)-2-propenoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid cancer, medullary × lenvatinib × Endocrine × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡